靶向5-脂氧合酶的衰老相关疾病药物研究进展
李旨珺1,2, 马彦辉1,2, 侯习习3, 姚团利1, 秦向阳2,*
1陕西科技大学化学与化工学院,西安 710021;2空军军医大学药学系化学制药学教研室,西安 710032;3西北大学生命科学院,西安 710068
摘要
随着老龄化社会进程的加快,延缓衰老或促进健康衰老已成为人类健康的重大需求。5-脂氧合酶(5-lipoxygenase, 5-LOX)是催化花生四烯酸生成重要炎性介质白三烯的关键酶。既往研究表明,5-LOX的异常激活和白三烯的过量产生与衰老相关炎症性疾病的发生与发展密切相关。因此,抑制5-LOX的激活可能是治疗年龄相关疾病的一种潜在策略。本文将对5-LOX激活、5-LOX介导衰老相关疾病及其小分子抑制剂三个方面的最新研究进行简要综述,以期为衰老相关炎症性疾病的防治提供理论基础和新思路。
关键词: 衰老; 炎性衰老; 衰老相关疾病; 5-脂氧合酶; 5-脂氧合酶抑制剂
Research progress in drugs targeting 5-lipoxygenase for age-related diseases
LI Zhi-Jun1,2, MA Yan-Hui1,2, HOU Xi-Xi3, YAO Tuan-Li1, QIN Xiang-Yang2,*
1School of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi’an 710021, China;2Department of Chemistry, School of Pharmacy, Air Force Medical University, Xi’an 710032, China;3College of Life Science, Northwestern University, Xi’an 710068, China
Abstract
With the acceleration of aging society, delaying aging or promoting healthy aging has become a major demand for human health. 5-Lipoxygenase (5-LOX) is a key enzyme catalyzing arachidonic acid into leukotrienes (LTs), which is a potent mediator of the inflammatory response. Previous studies showed that abnormal activation of 5-LOX and overproduction of LTs are closely related to the occurrence and development of aging-related inflammatory diseases. Therefore, inhibiting 5-LOX activation is a possibly potential strategy for treating age-related diseases. In this paper, the latest research progress in 5-LOX activation, 5-LOX in mediating aging- related diseases and its small molecule inhibitors is briefly reviewed to provide scientific theoretical basis and new ideas for the prevention and treatment of aging-related inflammatory diseases.
Key words: Aging; inflamm-aging; age-related disease; 5-lipoxygenase; 5-lipoxygenase inhibitor
收稿日期: 录用日期:
通讯作者:秦向阳 E-mail: qinxiangyang@fmmu.edu.cn
DOI: 10.13294/j.aps.2023.0075
引用本文:
李旨珺, 马彦辉, 侯习习, 姚团利, 秦向阳. 靶向5-脂氧合酶的衰老相关疾病药物研究进展[J]. 生理学报 2023; 75 (6): 864-876.
LI Zhi-Jun, MA Yan-Hui, HOU Xi-Xi, YAO Tuan-Li, QIN Xiang-Yang. Research progress in drugs targeting 5-lipoxygenase for age-related diseases. Acta Physiol Sin 2023; 75 (6): 864-876 (in Chinese with English abstract).